Erythromycin, a widely used macrolide antibiotic, is effective against various bacterial infections and also serves as a prokinetic agent for gastrointestinal disorders. Despite its efficacy, erythromycin is known for significant drug interactions due to its ability to inhibit the cytochrome P450 (CYP) enzyme system, particularly CYP3A4. These interactions can lead to altered pharmacokinetics of co-administered drugs, resulting in either reduced therapeutic efficacy or increased toxicity. This comprehensive review explores the pharmacokinetics and pharmacodynamics of erythromycin, identifies major drug interactions, and discusses the clinical implications of these interactions. Understanding these interactions is crucial for optimizing therapeutic outcomes and minimizing adverse effects.
HTML PDFShare this article
Journal of Diabetic Complications & Medicine received 102 citations as per Google Scholar report
